NCT01010399View on ClinicalTrials.gov

Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
HypertriglyceridemiaHIV Infection
Interventions
DIETARY_SUPPLEMENT

Lovaza

Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks

DRUG

fosamprenavir/ritonavir

Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day

Trial Locations (1)

93301

Franco Felizarta, MD, Bakersfield

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Felizarta, Franco, M.D.

INDIV

NCT01010399 - Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects | Biotech Hunter | Biotech Hunter